Physician profile
David Smith
NPI 1124175542
$9,188.66
in general payments reported to CMS, 2019-2025
25 companies · $499 in 2025
The $499 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,260 · 2020: $650 · 2021: $1,180 · 2022: $1,828 · 2023: $1,129 · 2024: $643 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,270.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,603.04 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $1,391.01 | 2019-2025 | Farxiga |
| Abbott Laboratories | $724.15 | 2019-2024 | Ensite Precision |
| Abbvie INC. | $638.04 | 2019-2021 | |
| Amgen INC. | $624.85 | 2019-2021 | |
| Esperion Therapeutics, INC. | $596.29 | 2020-2022 | |
| Boston Scientific Corporation | $499.94 | 2019-2025 | Avvigo Guidance System, Lux-Dx Insertable Cardiac Monitor |
| Edwards Lifesciences Corporation | $360.41 | 2024-2025 | |
| Amarin Pharma, INC. | $342.31 | 2019 | |
| Merck Sharp & Dohme LLC | $287.02 | 2020-2023 | Verquvo |
| Novo Nordisk INC | $226.55 | 2019-2022 | |
| Pfizer INC. | $222.55 | 2019 | |
| Glaxosmithkline, LLC. | $221.74 | 2019 | |
| Medicomp INC | $203.34 | 2023 | Telepatch Cardiac Monitor |
| Medtronic Vascular, INC. | $180.32 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $146.78 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Allergan, INC. | $127.36 | 2019 | |
| Gilead Sciences, INC. | $114.93 | 2019 | |
| Vifor Pharma, INC. | $113.54 | 2019 | |
| Abiomed | $112.50 | 2023 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.31 | 2021 | |
| Alnylam Pharmaceuticals INC. | $104.73 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $100.26 | 2019 | |
| Medtronic, INC. | $82.55 | 2021 | |
| Elutia, INC. | $53.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.